Acquired hemophilia A and von Willebrand syndrome in a patient with late-onset systemic lupus erythematosus
Authors:
- Christina DickeCDChristina Dicke
- Katharina HolsteinKHKatharina Holstein
- Sonja SchneppenheimSSSonja Schneppenheim
- Rita DittmerRDRita Dittmer
- Reinhard SchneppenheimRSReinhard Schneppenheim
- Carsten BokemeyerCBCarsten Bokemeyer
- Christof Iking-KonertCIChristof Iking-Konert
- Ulrich BuddeUBUlrich Budde
- Florian LangerFlorian Langer
Open Access
- 20 August 2014
- journal article
- case report
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 3 (1) , 21
Abstract
Acquired hemophilia A (AHA) and acquired von Willebrand Syndrome (AVWS) are both rare bleeding disorders that can be associated with lymphoproliferative or autoimmune diseases. AHA is uniformly caused by inhibitory autoantibodies against coagulation factor VIII (FVIII), while the pathophysiology of AVWS comprises several distinct mechanisms, including reduced synthesis, accelerated clearance, or increased proteolysis. In this regard, autoantibodies to von Willebrand factor (VWF) have been described in patients with systemic lupus erythematosus (SLE) or monoclonal gammopathy. Here, we report the case of a 71-year-old patient with a recent onset of spontaneous mucocutaneous and soft-tissue bleeding due to severely decreased FVIII and VWF. While there was no evidence for monoclonal gammopathy, specific IgG antibodies against both FVIII and VWF were detected. Furthermore, VWF multimer analysis revealed the presence of ultralarge plasma multimers and absence of the typical multimeric triplet structure, a finding consistent with decreased proteolytic processing of massively released, but rapidly cleared VWF. Both FVIII and VWF readily responded to immunosuppressive therapy with prednisolone. Interestingly, clinical and laboratory findings established the diagnosis of “late-onset SLE” in our patient. Thus, about 45 years after the first description of AVWS in a 12-year-old boy with SLE, we present another unusual case of concomitant autoimmune-mediated AHA and AVWS in an elderly SLE patient, which, to the best of our knowledge, has not been reported so far.Keywords
This publication has 22 references indexed in Scilit:
- Current Diagnostic and Therapeutic Approaches to Patients with Acquired von Willebrand Syndrome: A 2013 UpdateSeminars in Thrombosis and Hemostasis, 2013
- von Willebrand factor: the old, the new and the unknownJournal of Thrombosis and Haemostasis, 2012
- How I treat the acquired von Willebrand syndromeBlood, 2011
- Testing for lupus anticoagulants: all that a clinician should knowLupus, 2009
- Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up studyAnnals of the Rheumatic Diseases, 2009
- Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodiesArthritis Care & Research, 2008
- Systemic lupus erythematosus complicated by acquired von Willebrand’s syndromeLupus, 2008
- Immune-Mediated Etiology of Acquired von Willebrand Syndrome in Systemic Lupus Erythematosus and in Benign Monoclonal Gammopathy: Therapeutic ImplicationsSeminars in Thrombosis and Hemostasis, 2006
- Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1997
- Antibody‐induced von willebrand syndrome: Inhibition of VIII VWF and VIII AGN with sparing of VIII AHF by the autoanti bodyAmerican Journal of Hematology, 1978